28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Risk stratification for PET Aβ+ based on a plasma p-tau217 assay demonstrated potential diagnostic and prognostic utility in an Asian cohort with concomitant CeVD. 4 key findings →
Participants: 142 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease biomarkers are primarily evaluated through MRI, PET and CSF methods in order to diagnose and monitor disease. 3 key findings →
Design: cross-sectional Participants: 389 Evidence: moderate
Full summary, score breakdown and related studies → Original source
To identify whether platelet amyloid-β protein precursor (AβPP) ratio, phosphorylated-tau (P-tau) 231, P-tau181, and serine 396 and 404 (Ser396/404) phosphorylated tau are potential peripheral indicators for early Alzheimer's disease (AD). 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Niemann-Pick disease type C and Alzheimer's disease are distinct neurodegenerative disorders that share the presence of neurofibrillary tangle pathology. 4 key findings →
Design: cross-sectional Participants: 60 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The diagnostic value of neurofilament light chain protein in neurodegenerative dementia diseases is still controversial. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
We conclude that NPTX2 is a promising synapse-derived disease progression biomarker in genetic FTD. 3 key findings →
Design: longitudinal study Participants: 106 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We found a significant correlation between Tau (pTau) and neurodegeneration biomarkers (tTau and hippocampus volume) with GCL degeneration and, to a lesser degree, with damage in RFNL. 5 key findings →
Design: prospective cohort Participants: 99 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Several promising novel biomarkers were highlighted in this review. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
We reproduced subregion-specific FC profiles of the cBF in a clinical sample spanning the AD spectrum. 5 key findings →
Design: cohort study Participants: 477 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results confirm that PM20D1 is an mQTL in AD and demonstrate that it plays a dynamic role at different stages of the disease. 3 key findings →
Design: longitudinal study Participants: 649 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We determined 40% of sCJD urine sample results as positive. 4 key findings →
Design: cohort study Participants: 91 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study validated PrecivityAD2, a mass-spectrometry blood test made by C2N Diagnostics that combines two markers (%p-tau217 and the amyloid-beta 42/40 ratio) into a single 'Amyloid Probability Score 2.' 4 key findings →
Design: cross-sectional Participants: 583 Evidence: high
Full summary, score breakdown and related studies → Original source
Combining human cohort data (over 24,000 people) with mouse models, this study found that carrying the APOE2 gene variant is linked to a longer lifespan, and that this benefit holds even when accounting for Alzheimer's diagnosis and brain pathology. 4 key findings →
Design: cohort Participants: 24,661 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This Cochrane systematic review looked for solid evidence that respite care (temporary relief for caregivers) helps caregivers or people with dementia. 3 key findings →
Design: systematic-review Participants: 753 Evidence: null result
Full summary, score breakdown and related studies → Original source
Comparing two nationally representative surveys of older Americans 12 years apart, researchers found the share of seniors with dementia fell substantially, from 11.6% in 2000 to 8.8% in 2012. 4 key findings →
Design: cross-sectional Participants: 21,057 Evidence: high
Full summary, score breakdown and related studies → Original source
Researchers re-ran the same detailed dementia survey in the same three parts of England twenty years apart. 4 key findings →
Design: cross-sectional Participants: 15,431 Evidence: high
Full summary, score breakdown and related studies → Original source
By pooling two long-running community studies from the same region of Pennsylvania, researchers compared dementia rates across people born in different decades, from the 1900s to the 1940s. Each successively younger birth cohort had a substantially lower risk of developing dementia at a given age, with the youngest group's risk about a quarter of the oldest group's. This adds US evidence, independent of Framingham, that generational health improvements are lowering dementia risk. 4 key findings →
Design: cohort Participants: 3,010 Evidence: high
Full summary, score breakdown and related studies → Original source
This trial tested an antibody targeting tau tangles rather than amyloid plaques, in people with mild-to-moderate Alzheimer's. It slowed decline on one cognitive test by 42% compared with placebo, the first time an anti-tau antibody showed any cognitive benefit, but it did not help with daily-function scores, overall dementia staging (CDR-SB), or the MMSE, and it did not reduce tangle buildup seen on tau brain scans. 5 key findings →
Design: phase-2-trial Participants: 272 Evidence: preliminary
Full summary, score breakdown and related studies → Original source
This study tracked tau PET scans over time in over 800 people across the Alzheimer's spectrum and found that while tau broadly follows the classic 'Braak stage' spreading pattern, the exact regions affected vary a lot from person to person, especially as disease progresses. 4 key findings →
Design: cohort Participants: 832 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This 23-year study found a U-shaped relationship between alcohol and dementia risk: people who abstained from alcohol in midlife, as well as those who drank heavily (more than 14 units, about 14 standard drinks, per week), both had a higher risk of developing dementia than people who drank moderately. 4 key findings →
Design: cohort Participants: 9,087 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study underscores the substantial prevalence of loneliness and social isolation among informal carers of individuals with dementia. 3 key findings →
Design: meta-analysis Participants: 11,134 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This pilot randomized clinical trial demonstrated the feasibility, acceptability, and preliminary efficacy of LMH-4-DCP in reducing caregiver grief, with improvements in caregiver-care recipient relationship quality. 5 key findings →
Design: RCT Participants: 68 Evidence: preliminary
Full summary, score breakdown and related studies → Original source Free full text
This study found that a high-intensity multidomain lifestyle intervention did not affect brain biomarker trajectories and was not associated with Aβ pathology, but older adults with specific at-risk brain characteristics, including lower baseline HC volume, showed a greater cognitive benefit of the structured intervention. 4 key findings →
Design: RCT Participants: 983 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among older adults with diabetes, no clear evidence was found that the incidence of dementia differed overall between patients using GLP-1RAs versus DPP4is. 4 key findings →
Design: cohort Participants: 7,254 Evidence: early
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The mechanism of injury was a fall in 1 228 847 incidents (50.1%). 5 key findings →
Design: cohort Participants: 2,453,655 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →